~ Buy the TAUVID (flortaucipir f-18) Drug Profile, 2024 PDF Report in the Report Store ~

TAUVID Drug Patent Profile

Which patents cover Tauvid, and when can generic versions of Tauvid launch?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Tauvid

Tauvid was eligible for patent challenges on May 28, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TAUVID

International Patents:	26
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	9
Patent Applications:	9
What excipients (inactive ingredients) are in TAUVID?	TAUVID excipients list
DailyMed Link:	TAUVID at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAUVID

NDA:

212123

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAUVID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	Phase 1
Avid Radiopharmaceuticals	Phase 2
Avid Radiopharmaceuticals	Phase 1

See all TAUVID clinical trials

US Patents and Regulatory Information for TAUVID

TAUVID is protected by one US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAUVID

FDA Regulatory Exclusivity protecting TAUVID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		RX	Yes	Yes				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		RX	Yes	Yes
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		RX	Yes	Yes
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		RX	Yes	Yes				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-004	Jul 1, 2022		RX	Yes	Yes				Y

International Patents for TAUVID

When does loss-of-exclusivity occur for TAUVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Colombia

Croatia

Denmark

European Patent Office

Hungary

Japan

Lithuania

Poland

Portugal

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAUVID around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20150002854	CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION
Colombia	7131359	Agentes de imagen para detectar disfunción neurológica
European Patent Office	2247558	NOUVEAUX AGENTS D'IMAGERIE POUR LA DÉTECTION D'UNE DYSFONCTION NEUROLOGIQUE (NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION)
World Intellectual Property Organization (WIPO)	2009102498
Japan	2011512354